The marked impairment of SARS-CoV-2 neutralization activities among anti-TNF-treated IBD patients is a critical finding, as these could potentially lead to dismal protection from symptomatic SARS-CoV-2 infection and severe COVID-19 [12,13]. The gene discussed is TNF; the disease is inflammatory bowel disease.